Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

Life Sciences, Hematology, Oncology +12

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

John C. Byrd · Blood · 2002 · 1.6K citations

Medicine, Hematology, Oncology +16

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher et al. · Leukemia · 2012 · 915 citations · Full text

Medicine, Cell Biology, Hematology +15

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Michael J. Borowitz, Meenakshi Devidas, Stephen P. Hunger et al. · Blood · 2008 · 835 citations · Full text

Medicine, Oncology, Pediatrics +15

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl et al. · The Lancet Oncology · 2010 · 581 citations

Medicine, Hematology, Oncology +16